Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Non-Small-Cell Lung Cancer (Previously Treated; EGFR-Mutation-Positive/ALK-Translocation-Positive) | DecisionBase | US/EU5/Asia Pacific | 2015
In This Increasingly Crowded Setting, What Key Attributes Will Differentiate Emerging Therapies According to Oncologists and Payers? Treatment decisions for non-small-cell lung cancer (NSCLC)…
Global Consequences of Smoking Cessation: NSCLC Incidence over the Next Two Decades
The strongest risk factor that drives change in the incidence of non-small-cell lung cancer (NSCLC) is the historical prevalence of smoking. The long lag between the initiation of tobacco use and…
Non-Small-Cell Lung Cancer (Previously Treated EGFR Wild-Type/Untested) | Decision Base | US/EU | 2014
Of the Several Exciting Agents in Late-Stage Development, Do Any Have the Potential to Dramatically Improve Survival? Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of all…
Non-Small-Cell Lung Cancer (Previously Treated EGFR Wild-Type/Untested) | DecisionBase | US/EU5/Asia Pacific | 2014
Of the Several Exciting Agents in Late-Stage Development, Do Any Have the Potential to Dramatically Improve Survival? Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of all…
Contemporary Topics in the Treatment of Non-Small-Cell Lung Cancer: Physicians, Payers, and Pathologists as Gatekeepers to Market Access
Based on a survey of 100 medical oncologists and 30 MCO pharmacy and medical directors, this report explores the market access challenges facing key current and emerging brands used in the…
